Skip to main content
SpringerLink
Log in

Antidiabetika

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2019

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • American Diabetes Association (2019) 9. Pharmacological approaches to glycemic treatment. Standards of medical care in diabetes – 2019. Diabetes Care 42(Suppl 1):S90–S102

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2008) Pankreatitis unter Exenatid. Dtsch Arztebl 105:A 409

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2013) Aus der UAW-Datenbank: Zunahme von Spontanberichten über Metformin-assoziierte Laktatazidosen. Dtsch Arztebl 110:A 464 (http://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/20130308.html)

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2019) Risiko einer Fournier Gangrän (Nekrotisierende Fasziitis des Perineums) bei der Anwendung von SGLT2-Inhibitoren („Sodium-Glucose-Co-Transporter 2 Inhibitors“). https://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2019/index.html

    Google Scholar 

  • Bailey CJ (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32:63–71

    CAS  PubMed  Google Scholar 

  • Bertero E, Prates RL, Ameri P, Maack C (2018) Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res 114:12–18

    CAS  PubMed  Google Scholar 

  • Black C, Donnelly P, McIntyre L, Royle P, Shepherd J, Thomas S (2007) Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007 Apr 18; (2): CD004654

    Google Scholar 

  • Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C (2012) Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. Plos Med 9(4):e1001204. https://doi.org/10.1371/journal.pmed.1001204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2014) Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. Langfassung, 1. Auflage, Version 4, August 2013, zuletzt geändert: November 2014. http://www.leitlinien.de/nvl/diabetes/therapie

    Google Scholar 

  • Bundesinstitut für Arzneimittel und Medizinprodukte (2015) Metformin: Aktualisierung der Fach- und Gebrauchsinformation hinsichtlich der Kontraindikation bei Patienten mit eingeschränkter Nierenfunktion. http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RI/2015/RI-metformin.html

    Google Scholar 

  • Bundesministerium für Gesundheit (2010): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): – Anlage III – Übersicht der Verordnungseinschränkungen und -ausschlüsse Lang wirkende Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2 vom 18. März 2010, BAnz. Nr. 103 (S. 2422) vom 14. Juli 2010

    Google Scholar 

  • Bundesministerium für Gesundheit (2013a): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): – Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Dapagliflozin vom 6. Juni 2013 veröffentlicht am Dienstag, 16. Juli 2013, BAnz AT 16. Juli 2013 B2

    Google Scholar 

  • Bundesministerium für Gesundheit (2013b): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): – Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Lixisenatid vom 5. September 2013, veröffentlicht Mittwoch, 2. Oktober 2013, BAnz AT 2. Okt. 2013 B4

    Google Scholar 

  • Bundesministerium für Gesundheit (2016): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Empagliflozin vom 1. September 2016, veröffentlicht am Donnerstag, 15. September 2016 BAnz AT 15. Sept. 2016 B1

    Google Scholar 

  • Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47

    CAS  PubMed  Google Scholar 

  • Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381:117–124

    CAS  PubMed  Google Scholar 

  • Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM (1994) The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121:928–935

    CAS  PubMed  Google Scholar 

  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for the STOP-NIDDM Trail Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077

    CAS  PubMed  Google Scholar 

  • Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:2669–2701

    PubMed  PubMed Central  Google Scholar 

  • Deacon CF (2009) Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 5:199–211

    CAS  PubMed  PubMed Central  Google Scholar 

  • Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986

    Google Scholar 

  • Dills DG, Schneider J (1996) Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 28:426–429

    CAS  PubMed  Google Scholar 

  • Draeger KE, Wernicke-Panten K, Lomp H-J, Schüler E, Roßkamp R (1996) Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 28:419–425

    CAS  PubMed  Google Scholar 

  • Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705

    CAS  PubMed  Google Scholar 

  • Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240–1250

    CAS  PubMed  Google Scholar 

  • Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C (2014) Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 370:794–797

    CAS  PubMed  Google Scholar 

  • Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic and thyroid cancer with Glucagon-like peptide-1-based therapies. Baillieres Clin Gastroenterol 141:150–156

    CAS  Google Scholar 

  • Food and Drug Administration (2009) Information for health care professionals – Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm

    Google Scholar 

  • Food and Drug Administration (2014) FDA approves Farxiga to treat type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm

    Google Scholar 

  • Food and Drug Administration (2015) FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. http://www.fda.gov/drugs/drugsafety/ucm446845.htm

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2006) Medizinische Versorgung von Diabetes-Typ-2-Patienten gesichert. G-BA schützt Solidargemeinschaft vor überteuerten Pharmapreisen. Pressemitteilung vom 18.07.2006. http://www.g-ba.de/downloads/39-261-313/2006-07-18-AMR-Insulinanaloga_BAnz.pdf

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2008a) Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Sitagliptin vom 10. April 2008. Dtsch Arztebl 105:A 1801–A 1804

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2008b) Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Vildagliptin vom 18. Dezember 2008. Dtsch Arztebl 106:A 1581–A 1584

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2016) Arzneimittel-Richtlinie/Anlage III: Glinide zur Behandlung des Diabetes mellitus Typ 2 – Einstellung des Verfahrens vom 10.03.2015, Tragende Gründe. Beschlussdatum vom 18.02.2016. https://www.g-ba.de/informationen/beschluesse/2505/

    Google Scholar 

  • Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. https://doi.org/10.1016/S0140-6736

    Article  PubMed  Google Scholar 

  • Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242

    CAS  PubMed  Google Scholar 

  • Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519–1529

    CAS  PubMed  Google Scholar 

  • Hinnen D, Kruger DF (2019) Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. Diabetes Metab Syndr Obes 12:447–455

    CAS  PubMed  PubMed Central  Google Scholar 

  • Holman RR, Mayon White V, Orde-Peckar C, Steemson J, Smith B, Barbour D, McPherson K, Poon P, Rizza C, Mann JI, Knight AH, Bron AJ, Turner RC (1983) Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet 321:204–208

    Google Scholar 

  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589

    CAS  PubMed  Google Scholar 

  • Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C, ACE Study Group (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5:877–886

    CAS  PubMed  Google Scholar 

  • Institut für Wirtschaftlichkeit und Qualität im Gesundheitswesen (IQWiG) (2009) Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Abschlussbericht. http://www.iqwig.de/download/A05-03_Abschlussbericht_Langwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_2_V1.1.pdf

    Google Scholar 

  • Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117:574–584

    PubMed  Google Scholar 

  • Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE (2015) SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:90–100

    CAS  PubMed  Google Scholar 

  • Joffe HV (2009) Endocrinologic and metabolic drugs advisory committee meeting advisory committee, April 1 and April 2, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151114.pdf

    Google Scholar 

  • Keating GM (2005) Exenatide. Drugs 65:1681–1692

    CAS  PubMed  Google Scholar 

  • Van De Laar FA, Lucassen PL, Akkermans RP, Van De Lisdonk EH, Rutten GE, Van Weel C (2005) Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 Apr 18; (2): CD003639

    Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322

    CAS  PubMed  PubMed Central  Google Scholar 

  • Moses R (2000) A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 1:1455–1467

    CAS  PubMed  Google Scholar 

  • Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657

    CAS  PubMed  Google Scholar 

  • Phielix E, Szendroedi J, Roden M (2011) The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci 32:607–616

    CAS  PubMed  Google Scholar 

  • Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772

    CAS  PubMed  Google Scholar 

  • Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 4:753–768

    CAS  PubMed  PubMed Central  Google Scholar 

  • Scheen AJ (2018) Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122:1439–1459

    CAS  PubMed  PubMed Central  Google Scholar 

  • Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326

    CAS  PubMed  Google Scholar 

  • Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR (2004) Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004 Oct 18; (4): CD003287

    Google Scholar 

  • Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3:43–51

    CAS  PubMed  Google Scholar 

  • Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (2013) Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. Jama Intern Med 173:534–539

    CAS  PubMed  Google Scholar 

  • Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708

    CAS  PubMed  Google Scholar 

  • Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Holman RR (2000) Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321:405–412

    CAS  PubMed  PubMed Central  Google Scholar 

  • Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550–554

    CAS  PubMed  Google Scholar 

  • The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559

    PubMed Central  Google Scholar 

  • The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572

    Google Scholar 

  • The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group++ (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653

    Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a) Intensive glood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853

    Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865

    Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334

    CAS  PubMed  Google Scholar 

  • Warren E, Weatherley-Jones E, Chilcott J, Beverley C (2004) Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 8:1–57

    CAS  Google Scholar 

  • White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335

    CAS  PubMed  Google Scholar 

  • Wilde MI, McTavish D (1997) Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54:597–614

    CAS  PubMed  Google Scholar 

  • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357

    CAS  PubMed  Google Scholar 

  • Ziegler R, Neu A (2018) Diabetes mellitus im Kindes- und Jugendalter. Leitliniengerechte Diagnostik, Therapie und Langzeitbetreuung. Dtsch Ärztebl Int 115:146–156

    PubMed  PubMed Central  Google Scholar 

  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Heidelberg, Deutschland

    Prof. Dr. med. Marc Freichel

  2. Mannheim, Deutschland

    Dr. med. Klaus Mengel

Authors
  1. Prof. Dr. med. Marc Freichel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Freichel .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Köln, Nordrhein-Westfalen, Germany

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK, Berlin, Berlin, Germany

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Freichel, M., Mengel, K. (2019). Antidiabetika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2019. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59046-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59046-1_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59045-4

  • Online ISBN: 978-3-662-59046-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation